MovDisordV3, Main, Exploration, bibRecord, 003124

Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study

Identifieur interne : 003124 ( Main/Exploration ); précédent : 003123; suivant : 003125

Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study

Auteurs : Cecilia Peralta [Autriche] ; Elisabeth Wolf [Autriche] ; Hannes Alber [Autriche] ; Klaus Seppi [Autriche] ; Silvana Müller [Autriche] ; Sylvia Bösch [Autriche] ; Gregor K. Wenning [Autriche] ; Otmar Pachinger [Autriche] ; Werner Poewe [Autriche]

Source :

Movement Disorders [ 0885-3185 ] ; 2006-08.

RBID : ISTEX:3532767E0ADD9C18EDF04FEB17B35B98A3FD04AF

Descripteurs français

Pascal (Inist)
- Cardiopathie valvulaire, Echocardiographie, Parkinson maladie, Stimulant dopaminergique, Système nerveux pathologie.

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Cardiac valvular disease, Dopamine agonist, Echocardiography, Female, Heart Valve Diseases (epidemiology), Heart Valve Diseases (ultrasonography), Humans, Male, Middle Aged, Nervous system diseases, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (ultrasonography), Parkinson disease, Parkinson's disease, dopamine agonist, echocardiography, valvular heart disease.
MESH :
- chemical , adverse effects : Antiparkinson Agents.
- chemical , therapeutic use : Antiparkinson Agents.
- complications : Parkinson Disease.
- drug therapy : Parkinson Disease.
- epidemiology : Heart Valve Diseases.
- ultrasonography : Heart Valve Diseases, Parkinson Disease.
- Aged, Echocardiography, Female, Humans, Male, Middle Aged.

Abstract

Restrictive valvulopathy has been reported in association with dopamine agonist therapy in parkinsonian patients. The majority of reports have been related to pergolide, but anecdotal cases following treatment with bromocriptine or cabergoline have also been presented. It is presently unclear whether the potential induction of restrictive cardiac valvulopathy is a class effect of all dopamine agonists or if there is a differential risk between ergot and nonergot compounds. In this study, the frequency of a valvular regurgitation as assessed by routine transthoracic echocardiography was compared between 75 patients with Parkinson's disease (PD) treated with pergolide (n = 29), cabergoline (n = 13), pramipexole or ropinirole (n = 33), and 49 age‐matched nonparkinsonian controls. The exposure to pergolide and cabergoline was associated with higher frequencies of valvular regurgitation grades 2 and 3 (31% and 47%) compared with age‐matched controls (13%), while there was no increase of valvular regurgitation grades 2 and 3 in patients treated with nonergot compounds (10%). Evidence for restrictive valvulopathy was found in one patient treated with pergolide and cabergoline each. While this study shows similarly increased frequencies of valvular regurgitation in patients treated with the ergot agonists pergolide and cabergoline in comparison to both normal controls and patients treated with nonergot agonists, evidence for restrictive valvulopathy was only found in two cases. These results highlight the need for further prospective studies of the prevalence and underlying mechanisms of cardiac valvulopathy in PD patients treated with different dopamine agonists. © 2006 Movement Disorder Society

Url:

https://api.istex.fr/document/3532767E0ADD9C18EDF04FEB17B35B98A3FD04AF/fulltext/pdf

DOI: 10.1002/mds.20887

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study</title>
<author><name sortKey="Peralta, Cecilia" sort="Peralta, Cecilia" uniqKey="Peralta C" first="Cecilia" last="Peralta">Cecilia Peralta</name>
</author>
<author><name sortKey="Wolf, Elisabeth" sort="Wolf, Elisabeth" uniqKey="Wolf E" first="Elisabeth" last="Wolf">Elisabeth Wolf</name>
</author>
<author><name sortKey="Alber, Hannes" sort="Alber, Hannes" uniqKey="Alber H" first="Hannes" last="Alber">Hannes Alber</name>
</author>
<author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
</author>
<author><name sortKey="Muller, Silvana" sort="Muller, Silvana" uniqKey="Muller S" first="Silvana" last="Müller">Silvana Müller</name>
</author>
<author><name sortKey="Bosch, Sylvia" sort="Bosch, Sylvia" uniqKey="Bosch S" first="Sylvia" last="Bösch">Sylvia Bösch</name>
</author>
<author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
</author>
<author><name sortKey="Pachinger, Otmar" sort="Pachinger, Otmar" uniqKey="Pachinger O" first="Otmar" last="Pachinger">Otmar Pachinger</name>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><country>Autriche</country>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3532767E0ADD9C18EDF04FEB17B35B98A3FD04AF</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20887</idno>
<idno type="url">https://api.istex.fr/document/3532767E0ADD9C18EDF04FEB17B35B98A3FD04AF/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001789</idno>
<idno type="wicri:Area/Istex/Curation">001789</idno>
<idno type="wicri:Area/Istex/Checkpoint">001B83</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Peralta C:valvular:heart:disease</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16622856</idno>
<idno type="wicri:Area/PubMed/Corpus">002C91</idno>
<idno type="wicri:Area/PubMed/Curation">002C91</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002A32</idno>
<idno type="wicri:Area/Ncbi/Merge">001643</idno>
<idno type="wicri:Area/Ncbi/Curation">001643</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001643</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Peralta C:valvular:heart:disease</idno>
<idno type="wicri:Area/Main/Merge">004437</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0435077</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A61</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001260</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001846</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Peralta C:valvular:heart:disease</idno>
<idno type="wicri:Area/Main/Merge">004941</idno>
<idno type="wicri:Area/Main/Curation">003124</idno>
<idno type="wicri:Area/Main/Exploration">003124</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study</title>
<author><name sortKey="Peralta, Cecilia" sort="Peralta, Cecilia" uniqKey="Peralta C" first="Cecilia" last="Peralta">Cecilia Peralta</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wolf, Elisabeth" sort="Wolf, Elisabeth" uniqKey="Wolf E" first="Elisabeth" last="Wolf">Elisabeth Wolf</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Alber, Hannes" sort="Alber, Hannes" uniqKey="Alber H" first="Hannes" last="Alber">Hannes Alber</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Cardiology, Innsbruck Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Muller, Silvana" sort="Muller, Silvana" uniqKey="Muller S" first="Silvana" last="Müller">Silvana Müller</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Cardiology, Innsbruck Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bosch, Sylvia" sort="Bosch, Sylvia" uniqKey="Bosch S" first="Sylvia" last="Bösch">Sylvia Bösch</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pachinger, Otmar" sort="Pachinger, Otmar" uniqKey="Pachinger O" first="Otmar" last="Pachinger">Otmar Pachinger</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Cardiology, Innsbruck Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-08">2006-08</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="1109">1109</biblScope>
<biblScope unit="page" to="1113">1113</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">3532767E0ADD9C18EDF04FEB17B35B98A3FD04AF</idno>
<idno type="DOI">10.1002/mds.20887</idno>
<idno type="ArticleID">MDS20887</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Cardiac valvular disease</term>
<term>Dopamine agonist</term>
<term>Echocardiography</term>
<term>Female</term>
<term>Heart Valve Diseases (epidemiology)</term>
<term>Heart Valve Diseases (ultrasonography)</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (ultrasonography)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>dopamine agonist</term>
<term>echocardiography</term>
<term>valvular heart disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Heart Valve Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="ultrasonography" xml:lang="en"><term>Heart Valve Diseases</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Echocardiography</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cardiopathie valvulaire</term>
<term>Echocardiographie</term>
<term>Parkinson maladie</term>
<term>Stimulant dopaminergique</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Restrictive valvulopathy has been reported in association with dopamine agonist therapy in parkinsonian patients. The majority of reports have been related to pergolide, but anecdotal cases following treatment with bromocriptine or cabergoline have also been presented. It is presently unclear whether the potential induction of restrictive cardiac valvulopathy is a class effect of all dopamine agonists or if there is a differential risk between ergot and nonergot compounds. In this study, the frequency of a valvular regurgitation as assessed by routine transthoracic echocardiography was compared between 75 patients with Parkinson's disease (PD) treated with pergolide (n = 29), cabergoline (n = 13), pramipexole or ropinirole (n = 33), and 49 age‐matched nonparkinsonian controls. The exposure to pergolide and cabergoline was associated with higher frequencies of valvular regurgitation grades 2 and 3 (31% and 47%) compared with age‐matched controls (13%), while there was no increase of valvular regurgitation grades 2 and 3 in patients treated with nonergot compounds (10%). Evidence for restrictive valvulopathy was found in one patient treated with pergolide and cabergoline each. While this study shows similarly increased frequencies of valvular regurgitation in patients treated with the ergot agonists pergolide and cabergoline in comparison to both normal controls and patients treated with nonergot agonists, evidence for restrictive valvulopathy was only found in two cases. These results highlight the need for further prospective studies of the prevalence and underlying mechanisms of cardiac valvulopathy in PD patients treated with different dopamine agonists. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
</country>
<region><li>Tyrol (Land)</li>
</region>
<settlement><li>Innsbruck</li>
</settlement>
<orgName><li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree><country name="Autriche"><noRegion><name sortKey="Peralta, Cecilia" sort="Peralta, Cecilia" uniqKey="Peralta C" first="Cecilia" last="Peralta">Cecilia Peralta</name>
</noRegion>
<name sortKey="Alber, Hannes" sort="Alber, Hannes" uniqKey="Alber H" first="Hannes" last="Alber">Hannes Alber</name>
<name sortKey="Bosch, Sylvia" sort="Bosch, Sylvia" uniqKey="Bosch S" first="Sylvia" last="Bösch">Sylvia Bösch</name>
<name sortKey="Muller, Silvana" sort="Muller, Silvana" uniqKey="Muller S" first="Silvana" last="Müller">Silvana Müller</name>
<name sortKey="Pachinger, Otmar" sort="Pachinger, Otmar" uniqKey="Pachinger O" first="Otmar" last="Pachinger">Otmar Pachinger</name>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
<name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<name sortKey="Wolf, Elisabeth" sort="Wolf, Elisabeth" uniqKey="Wolf E" first="Elisabeth" last="Wolf">Elisabeth Wolf</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003124 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003124 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:3532767E0ADD9C18EDF04FEB17B35B98A3FD04AF
   |texte=   Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study

Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.